Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.105 USD | -4.08% | +2.20% | +0.18% |
06-20 | JMP Securities Adjusts Price Target on Iovance Biotherapeutics to $23 From $25, Maintains Market Outperform Rating | MT |
06-11 | Iovance Biotherapeutics, Inc. Elects Frederick G. Vogt as Director | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.18% | 2.36B | |
-40.74% | 7.63B | |
+8.65% | 3.61B | |
-24.56% | 1.86B | |
-18.18% | 1.74B | |
+5.50% | 913M | |
+15.75% | 763M | |
-10.48% | 678M | |
-0.60% | 290M | |
-24.11% | 150M |
- Stock Market
- Equities
- IOVA Stock
- News Iovance Biotherapeutics, Inc.
- Iovance Biotherapeutics Pauses Lung Cancer Trial Following FDA's Clinical Hold